Aptose Biosciences Updates Acquisition Timeline, Secures $11.1M Financing from Acquirer Hanmi

summarizeSummary

Aptose Biosciences updated its acquisition timeline, rescheduling the shareholder meeting to March 31, 2026, and secured a critical US$11.1 million financing facility from its acquirer, Hanmi Pharmaceutical, to fund ongoing operations.

check_boxKey Events

• Acquisition Meeting Postponed

  The special meeting of shareholders to approve the acquisition by HS North America Ltd. (a Hanmi subsidiary) has been postponed from January 16, 2026, to March 31, 2026, to address SEC comments on the transaction statement.

• Secured US$11.1 Million Financing

  Aptose entered into a US$11.1 million second amended and restated uncommitted facility agreement with Hanmi Pharmaceutical. These funds are designated for business and clinical operations expenses related to the advancement of Tuspetinib until May 31, 2026.

• Financial Hardship Exemption Utilized

  The company relied on a 'financial hardship' exemption under MI 61-101 for this and prior facility agreements, highlighting the critical nature of this financing for its continued operations.

auto_awesomeAnalysis

Aptose Biosciences has amended its arrangement agreement with Hanmi Pharmaceutical, postponing the shareholder meeting for the acquisition to March 31, 2026. This delay is to address comments from the SEC. Concurrently, the company secured a substantial US$11.1 million second amended and restated facility agreement from Hanmi. This uncommitted financing, significantly larger than Aptose's current market capitalization, is crucial for funding ongoing business and clinical operations, particularly for the Tuspetinib program, as the company continues towards the acquisition. The reliance on a 'financial hardship' exemption for this and prior facility agreements underscores the critical need for this capital to maintain operations.